
Opinion|Videos|August 5, 2024
Improving Insurance Coverage for RSV Vaccines
The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?
- How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?
- How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
- How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
3
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
4
Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP
5